Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zeltiq

This article was originally published in Start Up

Executive Summary

Zeltiq was founded to commercialize technology based on research demonstrating that fat cells are more susceptible than other types of cells to extreme cold and can be selectively, painlessly and permanently destroyed in a process known as cryolipolysis. With FDA 510(k) clearance for its CoolSculpting system in hand in early September, Zeltiq hopes to lead the charge into the body contouring aesthetics frontier with a technology that it believes stands apart from emerging laser, radiofrequency and ultrasound systems.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel